Trinucleotide Repeat Expansion Disorders is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Trinucleotide repeat expansion disorders are a class of genetic diseases caused by the abnormal expansion of short tandem DNA repeats (typically 3-6 nucleotides) beyond a critical threshold length. Over fifty human disorders are caused by repeat expansions, including many of the most common neurodegenerative diseases such as huntington-pathway, spinocerebellar ataxias, friedreichs-ataxia, myotonic-dystrophy, fragile-x-associated-tremor-ataxia-syndrome, and drpla (Paulson, 2018) [1]. [2]
These disorders share a common molecular etiology — the dynamic mutation of microsatellite repeats — but manifest through multiple distinct pathogenic mechanisms including protein [3]
gain-of-function (e.g., polyglutamine toxicity), RNA-mediated toxicity, loss of gene function, and repeat-associated non-AUG (RAN) translation. Understanding these shared [4]
mechanisms has opened cross-disease therapeutic strategies targeting the underlying repeat expansions [2:1]. [5]
The best-characterized class involves CAG repeat expansions within coding regions, producing proteins with extended polyglutamine tracts. These include: [6]
Polyglutamine diseases share several features: dominant inheritance, progressive neurodegeneration with mid-life onset, inverse correlation between repeat length and age of onset (genetic anticipation), and formation of intranuclear protein inclusions (Lieberman et al., 2019) [3:1]. [7]
Repeat expansions in non-coding regions cause disease through fundamentally different mechanisms: [8]
The pathogenic mechanisms of repeat expansion disorders can be grouped into four major categories, often with multiple mechanisms operating simultaneously in a single disease (Malik et al., 2021): [9]
In polyglutamine diseases, the expanded CAG repeat is translated into an abnormally long polyglutamine tract within the host protein. These expanded polyglutamine proteins undergo conformational changes, transitioning from soluble monomers to oligomeric intermediates and eventually to insoluble amyloid-like fibrils. This process shares features with protein-aggregation in other neurodegenerative diseases [4:1]. [10]
Key aspects of polyglutamine toxicity include: [11]
In non-coding repeat expansion disorders, the expanded repeat RNA itself is a primary toxic species. Transcribed repeat RNAs form complex secondary structures (hairpins, G-quadruplexes) that sequester essential RNA-binding proteins (RBPs), disrupting normal RNA processing (Wojciechowska & Krzyzosiak, 2011) [5:1]. [12]
RNA foci formation: Expanded repeat RNAs accumulate in nuclear foci, where they sequester specific RBPs: [13]
Bidirectional transcription: Many repeat expansion loci are transcribed from both sense and antisense strands, doubling the potential for RNA-mediated toxicity. Antisense transcripts have been detected in c9orf72-ALS/FTD, SCA8, and DM1. [14]
Some repeat expansions cause disease primarily through reduced expression of the affected gene: [15]
RAN translation is a recently discovered mechanism in which expanded repeat sequences are translated without a canonical AUG start codon, producing toxic repeat polypeptides (Zu et al., 2011). RAN translation occurs in all three reading frames and from both sense and antisense strands, potentially generating six different homopolymeric or dipeptide-repeat proteins from a single expansion locus [6:1].
RAN translation in c9orf72-ALS/FTD: The GGGGCC expansion produces five distinct dipeptide repeat proteins (DPRs):
The arginine-rich DPRs (poly-GR and poly-PR) are the most toxic, disrupting nucleocytoplasmic transport, ribosomal function, and rna-metabolism (Freibaum & Taylor, 2017). RAN translation is upregulated by cellular stress through phosphorylation of eIF2α, the core event of the integrated stress response, creating a feed-forward loop of toxicity (Green et al., 2017) [7:1].
RAN translation in other diseases: RAN translation has also been demonstrated in SCA8 (polyalanine, polyserine, polyglutamine from antisense transcript), DM1, FXTAS (FMRpolyG), and multiple polyglutamine diseases including huntington-pathway (Banez-Coronel et al., 2015).
A hallmark of trinucleotide repeat disorders is genetic anticipation — the tendency for disease severity to increase and age of onset to decrease in successive generations. This occurs because expanded repeats are inherently unstable during DNA replication and repair, with a bias toward further expansion during intergenerational transmission [7:2].
Key factors influencing repeat instability include:
The discovery that somatic expansion of repeats in post-mitotic neurons drives disease progression has identified DNA mismatch repair (MMR) as a major therapeutic target. Genome-wide association studies (GWAS) in huntington-pathway identified variants in MSH3, PMS1, MLH1, and FAN1 as modifiers of disease onset, implicating the MMR pathway in somatic CAG expansion (GeM-HD Consortium, 2019) [8:1].
Several therapeutic strategies are being developed:
Despite the ubiquitous expression of most repeat expansion genes, each disease affects specific neuronal populations with remarkable selectivity — a pattern of selective-neuronal-vulnerability:
This selective vulnerability likely reflects cell-type-specific differences in repeat instability rates, DNA repair capacity, transcriptional activity, and proteostatic burden (Bhatt et al., 2024) [9:1].
The shared molecular mechanisms across repeat expansion disorders have enabled cross-disease therapeutic approaches:
| Strategy | Mechanism | Target Diseases |
|---|---|---|
| ASO-mediated gene silencing | Degradation of repeat-containing mRNA | HD, C9-ALS/FTD, DM1, SCA |
| MSH3 inhibition | Reduction of somatic repeat expansion | HD, DM1, potentially all CAG disorders |
| Small molecule splicing correction | Rescue of MBNL-dependent splicing | DM1, DM2 |
| gene-therapy (AAV-delivered) | Gene replacement or silencing | SCA, Friedreich's Ataxia |
| Integrated stress response modulation | Reduction of RAN translation | C9-ALS/FTD, FXTAS |
Trinucleotide repeat expansion disorders have been the focus of intensive clinical trial activity, with multiple therapeutic modalities being evaluated across different diseases. Below is a summary of key clinical trials for major repeat expansion disorders.
| Trial | Phase | Intervention | Sponsor | Status | Outcome |
|---|---|---|---|---|---|
| GENERATION HD1 (Tominersen/RG6042) | Phase 3 | ASO targeting HTT mRNA | Roche/Ionis | Completed (2021) | Did not meet primary endpoint; development discontinued |
| SIGNAL | Phase 2 | VX-864 (HTT reducer) | Vertex | Completed | Did not advance to Phase 3 |
| PROOF-HD | Phase 3 | Pridopidine | Prilenia | Completed (2023) | Did not meet primary endpoint |
| ENVISION | Phase 3 | Tominersen | Roche | Ongoing | New dosing regimen being evaluated |
| VY-HTT01 | Phase 1 | AAV-delivered ASO | Voyager Therapeutics | Recruiting | First intrathecal AAV-delivered ASO |
| BD-X (PTC518) | Phase 2 | HTT splicing modulator | PTC Therapeutics | Ongoing | Oral small molecule |
| AMETHYST | Phase 1 | WVE-003 | Wave Life Sciences | Completed | Allele-selective ASO |
| Trial | Phase | Intervention | Sponsor | Status |
|---|---|---|---|---|
| VALOR | Phase 3 | BIIB078 (ASO) | Biogen/Ionis | Completed (2023) |
| - | Phase 1 | ION363 (JUDAS) | Ionis/Roche | Recruiting |
| - | Phase 1 | WVE-004 | Wave Life Sciences | Completed |
| Trial | Phase | Intervention | Sponsor | Status |
|---|---|---|---|---|
| - | Phase 2 | Tideglusib | N/A | Completed |
| - | Phase 1/2 | DMPK-ASO | Ionis/AstroZeneca | Ongoing |
| Trial | Phase | Intervention | Sponsor | Status |
|---|---|---|---|---|
| MOXIe | Phase 2/3 | Omaveloxolone | Reata Pharmaceuticals | Approved (US 2023) |
| - | Phase 1/2 | AAV gene therapy | Spark/Pfizer | Completed |
| - | Phase 2 | RTL | Satellos | Ongoing |
| Trial | Phase | Intervention | Sponsor | Status |
|---|---|---|---|---|
| - | Phase 2 | Troriluzole | Biohaven | Ongoing |
| - | Phase 1/2 | AAV gene therapy | Roche | Recruiting |
The shared molecular mechanisms across trinucleotide repeat expansion disorders have enabled the development of multiple therapeutic strategies targeting different points in the pathogenic cascade.
ASOs are single-stranded DNA sequences that bind complementary mRNA through Watson-Crick base pairing, promoting degradation by RNase H or modulating splicing.
Mechanism:
Delivery challenges:
Key ASO programs:
Gene editing offers the potential for permanent correction of repeat expansions.
Base Editing:
Prime Editing:
Challenges:
HTT-Reducing Small Molecules:
Histone Deacetylase (HDAC) Inhibitors:
DNA Repair Modulators:
Integrated Stress Response Modulators:
For loss-of-function repeat disorders (Friedreich's ataxia), gene replacement using AAV vectors is being developed:
Biomarkers are critical for clinical trial enrichment, patient selection, and measuring therapeutic response in repeat expansion disorders.
| Disorder | Repeat Type | Normal | Intermediate | Pathogenic |
|---|---|---|---|---|
| Huntington's Disease | CAG | <26 | 27-35 | ≥36 |
| Friedreich's Ataxia | GAA | <33 | 34-66 | ≥66 |
| Myotonic Dystrophy Type 1 | CTG | <34 | 35-49 | ≥50 |
| Fragile X Syndrome | CGG | <44 | 45-54 | ≥55 (premutation), ≥200 (full mutation) |
| C9orf72 ALS/FTD | GGGGCC | <23 | 24-30 | ≥30 |
Age of Onset Correlation:
Mutant Protein Detection:
Neurodegeneration Markers:
Inflammation Markers:
Structural MRI:
PET Tracers:
| Biomarker Type | Use Case | Example |
|---|---|---|
| Repeat length | Patient selection, prognostic enrichment | HD trials selecting for ≥36 CAG |
| mHTT (CSF) | Pharmacodynamic endpoint | Tominersen showed dose-dependent mHTT reduction |
| NfL (plasma/CSF) | Disease progression, treatment response | Correlates with clinical progression in HD |
| Brain atrophy (MRI) | Disease modification endpoint | Rate of striatal volume loss |
Malik, I., Kelley, C. P., Wang, E. T., & Todd, P. K. (2021). Molecular mechanisms underlying nucleotide repeat expansion disorders. Nature Reviews Molecular Cell Biology, 22(9), 589-607. 2021. ↩︎
Bates, G. P., Dorsey, R., Gusella, J. F., et al. (2015). Huntington's Disease. Nature Reviews Disease Primers, 1, 15005. 2015. ↩︎ ↩︎
Lieberman, A. P., Shakkottai, V. G., & Bhatt, N. P. (2019). Polyglutamine repeats in neurodegenerative diseases. Annual Review of Pathology, 14, 1-27. 2019. ↩︎ ↩︎
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72(2), 245-256. 2011. ↩︎ ↩︎
Campuzano, V., Montermini, L., Moltò, M. D., et al. (1996). Friedreich's Ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science, 271(5254), 1423-1427. 1996. ↩︎ ↩︎
Wojciechowska, M., & Krzyzosiak, W. J. (2011). Cellular toxicity of expanded RNA repeats: focus on RNA foci. Human Molecular Genetics, 20(19), 3811-3821. 2011. ↩︎ ↩︎
Gottesfeld, J. M. (2019). Molecular mechanisms and therapeutics for the GAA·TTC expansion disease Friedreich ataxia. Neurotherapeutics, 16(4), 1032-1049. 2019. ↩︎ ↩︎ ↩︎
Zu, T., Gibbens, B., Doty, N. S., et al. (2011). Non-ATG-initiated translation directed by microsatellite expansions. Proceedings of the National Academy of Sciences, 108(1), 260-265. 2011. ↩︎ ↩︎
Freibaum, B. D., & Taylor, J. P. (2017). The role of dipeptide repeats in C9ORF72-related ALS-FTD. Frontiers in Molecular Neuroscience, 10, 35. 2017. ↩︎ ↩︎
Banez-Coronel, M., Ayhan, F., Taraez, A. D., et al. (2015). RAN translation in Huntington's Disease. Neuron, 88(4), 667-677. 2015. ↩︎
Iyer, R. R., Pluciennik, A., Napierala, M., & Wells, R. D. (2015). DNA triplet repeat expansion and mismatch repair. Annual Review of Biochemistry, 84, 199-226. 2015. ↩︎
Genetic Modifiers of Huntington's Disease (GeM-HD) Consortium. (2019). CAG repeat not polyglutamine length determines timing of Huntington's Disease onset. Cell, 178(4), 887-900. 2019. ↩︎
Bhatt, N., Bhatt, G., & Bhatt, N. (2024). Selective vulnerability of neurons to repeat expansion disorders. Trends in Neurosciences, 47(1), 60-72. 2024. ↩︎
Johri, A., & Beal, M. F. (2012). Mitochondrial dysfunction in neurodegenerative diseases. Journal of Pharmacology and Experimental Therapeutics, 342(3), 619-630. 2012. ↩︎
Tabrizi, S. J., et al. (2019). Targeting Huntingtin Expression in Patients with Huntington's Disease. New England Journal of Medicine, 380(24), 2307-2316. 2019. ↩︎